To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05576077
Title A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors (STARLING)
Acronym STARLING
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Turnstone Biologics, Corp.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | CAN

Facility Status City State Zip Country Details
University of California Irvine Irvine California 92868 United States Details
Memorial Healthcare System Hollywood Florida 33021 United States Details
University of Miami Miami Florida 33136 United States Details
Orlando Health Orlando Florida 32806 United States Details
Moffitt Cancer Center Tampa Florida 33612-9497 United States Details
University of Chicago Chicago Illinois 60637 United States Details
Norton Cancer Institute Louisville Kentucky 40202 United States Details
Providence Cancer Institute Portland Oregon 97213 United States Details
Allegheny Research Institute Pittsburgh Pennsylvania 15224 United States Details
MD Anderson Cancer Center Houston Texas 77030 United States Details
Medical College of Wisconsin Milwaukee Wisconsin 53226 United States Details
Princess Margaret Cancer Centre Toronto Ontario M5G 2C1 Canada Details
Montreal University Hospital Center Montréal Quebec H2X 0C1 Canada Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field